Arthur M Krieg

Arthur M Krieg is a Professor at the RNA Therapeutics Institute within UMass Chan Medical School and T.H. Chan School of Medicine. He holds an MD from Washington University School of Medicine and a BS in Biology from Haverford College. His primary research focuses on nucleic acid therapeutics, immunotherapy, and oncology, with extensive work on Toll-like receptor (TLR) agonists and CpG oligonucleotides.

Dr. Krieg's research explores cancer immunotherapy mechanisms, nucleic acid-based drug development, and therapeutic applications of TLR agonists. His work bridges molecular biology and clinical applications, emphasizing immune modulation strategies for oncology and infectious diseases.

Recent publications demonstrate a focus on clinical translation of TLR9 agonists (vidutolimod) for PD-1-resistant cancers, antisense oligonucleotide therapies for genetic disorders, and immunotherapy combinations. Trends include biomarker development, machine learning applications in oncology, and novel therapeutic combinations.